Scientific considerations concerning the EMA change in the definition of “dose” of the BCS-based biowaiver guideline and implications for bioequivalence-Reference-Cited by-同舟云学术

Scientific considerations concerning the EMA change in the definition of “dose” of the BCS-based biowaiver guideline and implications for bioequivalence

Published:2015-01 Issue:2 Volume:478 Page:606-609
ISSN:0378-5173
Container-title:International Journal of Pharmaceutics
language:en
Short-container-title:International Journal of Pharmaceutics

Author:

Daousani Chrysa,Macheras Panos

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference23 articles.

1. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability;Amidon;Pharm. Res.,1995

2. The developability classification system: application of biopharmaceutics concepts to formulation development;Butler;J. Pharm. Sci.,2010

3. Supersaturated dissolution data and their interpretation: the TPGS-carbamazepine model case;Charkoftaki;J. Pharm. Pharmacol.,2011

4. Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS;Charkoftaki;Pharm. Res.,2012

5. A population growth model of dissolution;Dokoumetzidis;Pharm. Res.,1997

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biowaiver based on biopharmaceutics classification system: Considerations and requirements;Pharmaceutical Science Advances;2024-12

2. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines;International Journal of Pharmaceutics;2019-07

3. Escenario actual de los medicamentos biocomparables en México: posicionamiento del Colegio Mexicano de Reumatología, 2016;Reumatología Clínica;2018-05

4. A reaction limited in vivo dissolution model for the study of drug absorption: Towards a new paradigm for the biopharmaceutic classification of drugs;European Journal of Pharmaceutical Sciences;2018-05

5. Current State of Biosimilars in Mexico: The Position of the Mexican College of Rheumatology, 2016;Reumatología Clínica (English Edition);2018-05